# A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients

> **NCT05441553** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Vitalgen BioPharma Co., Ltd.** · enrollment: 26 (estimated)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** VGB-R04

## Key facts

- **NCT ID:** NCT05441553
- **Lead sponsor:** Shanghai Vitalgen BioPharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07
- **Primary completion:** 2025-01
- **Final completion:** 2025-01
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05441553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05441553, "A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05441553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*